數(shù)量:大量
ATCC Number:HB-9147?
運輸方式:凍存運輸
生長狀態(tài):懸浮生長
是否是腫瘤細胞:0
物種來源:小鼠
細胞形態(tài):淋巴樣
免疫類型:IgG2a and 2b , IgG2a; IgG2b
規(guī)格:0.3ml Designations: OVB-3 [OVB3]
Depositors: ?The United States of America
Isotype: IgG2a and 2b , IgG2a; IgG2b
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension, suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against human ovarian carcinoma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments:Animals were immunized with OVCAR-3 cells (see NIH:OVCAR-3, ATCC HTB-161 ).
Spleen cells were fused with NS-1 myeloma cells.
The antibody cross-reacts with various normal and neoplastic tissues.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10(5) cells/ml and maintain between 1 X 10(5) and 1 X 10(6) cells/ml.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 1814: Willingham MC, et al. Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model. Proc. Natl. Acad. Sci. USA 84: 2474-2478, 1987. PubMed: 3104916
1815: Pearson JW, et al. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res. 49: 4990-4995, 1989. PubMed: 2504482
4012: Fitzgerald DJ, et al. Monoclonal antibody against ovarian cancer cells (OVB-3). US Patent 4,806,494 dated Feb 21 1989